EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of EDIII-based subunit vaccine candidate for West Nile virus, its evaluation for immunogenicity, neutralizing potential and cross-reactive antibody responses

Muskan Kumari, Archana Rout, Anjali Saroj, Rishav Madhukalya, Disharee Mallick, Dilip Kumar, Rajesh Kumar

The Microbe · 2026-12 · 13 · 100824

DOI: 10.1016/j.microb.2026.100824 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Microbe, 2026-12. Verfasst von Muskan Kumari und 6 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: LifeArc.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The envelope glycoprotein E is a key target for eliciting neutralizing antibody responses in flavivirus infections. Several investigations have found that antibodies can neutralize virus particles after binding to a set of distinct epitopes on all three domains of the E glycoprotein. Developing an efficient method to purify and isolate surface-exposed viral antigens, particularly the envelope domain III (EDIII) of surface glycoprotein E, is important for advancing the development of subunit vaccine candidates. In this study, we present an approach for high-level recombinant protein production, chromatographic purification, and urea-gradient refolding of the EDIII protein of WNV using a prokaryotic expression system. The EDIII protein was recovered from insoluble inclusion bodies (IBs) and then purified through affinity chromatography. Following purification, the denatured protein was refolded through stepwise buffer exchange in urea dilution. Structural analysis of the refolded protein was performed via Fourier-Transform Infrared (FTIR) and Circular Dichroism (CD) Spectroscopy. The FTIR and CD data validated that the refolded EDIII protein retains its native-like secondary structure and is predominantly composed of β-strands. Additionally, the biological activity of the refolded protein was evaluated by a competitive plaque inhibition assay, and its immunogenicity was tested in a mouse model. The serum obtained from immunized mice was used to quantify cross-reactive antibody responses via ELISA, and functional efficacy was tested in neutralization assays, where mouse sera neutralized WNV with a plasma inhibitory dose 50 (ID 50 ) value of 160, confirming a robust antibody response. Overall, this work highlights an effective strategy for producing recombinant EDIII protein, supporting its potential application as a subunit vaccine candidate against WNV.

Förderung

  • LifeArc

Zitieren

APA

Kumari, M., Rout, A., Saroj, A., Madhukalya, R., Mallick, D., Kumar, D., & Kumar, R. (2026). Development of EDIII-based subunit vaccine candidate for West Nile virus, its evaluation for immunogenicity, neutralizing potential and cross-reactive antibody responses. The Microbe, 13, 100824. https://doi.org/10.1016/j.microb.2026.100824

Vancouver

Kumari M, Rout A, Saroj A, Madhukalya R, Mallick D, Kumar D, et al. Development of EDIII-based subunit vaccine candidate for West Nile virus, its evaluation for immunogenicity, neutralizing potential and cross-reactive antibody responses. The Microbe. 2026;13:100824. doi:10.1016/j.microb.2026.100824

BibTeX
@article{Kumari2026,
  author = {Kumari, Muskan and Rout, Archana and Saroj, Anjali and Madhukalya, Rishav and Mallick, Disharee and Kumar, Dilip and Kumar, Rajesh},
  title = {Development of EDIII-based subunit vaccine candidate for West Nile virus, its evaluation for immunogenicity, neutralizing potential and cross-reactive antibody responses},
  journal = {The Microbe},
  year = {2026},
  volume = {13},
  pages = {100824},
  doi = {10.1016/j.microb.2026.100824}
}
Kostenlos starten →